Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research on cells’ ’power centers’ sheds light on AIDS treatments

10.10.2002


Companies that create HIV-AIDS drugs now have key information that could assist in making new medications with fewer side effects.



Researchers Henry Weiner, a professor of biochemistry at Purdue University, Steven Zollo of the National Institute of Standards and Technology and Lauren Wood of the National Cancer Institute, noted the similarity between HIV-AIDS treatment side effects and naturally occurring diseases. Certain HIV-AIDS treatment side effects, such as fat loss and insulin resistance, clinically resemble diseases of the mitochondria, the "power centers" in cells, that affect the functioning of other parts of the cell.

The researchers hypothesized that the drugs to combat HIV infection also might inadvertently affect the functioning of the mitochondria.


"Finding that a drug affects a different target than the one it was designed for is not unusual," said Weiner, an expert on protein processing in the mitochondria. The team speculated that current AIDS treatments using drugs that inhibit HIV proteins also could inhibit a key mitochondrial protein.

This speculation fits the observation by doctors that side effects resembling mitochondrial dysfunction originated after new drugs became part of the standard drug "cocktail" used to treat AIDS patients. Highly Active Antiretroviral Therapy, or HAART, has prolonged the lives of many, but also has been associated with side effects such as diabetes, high cholesterol and the development of fatty deposits.

To test the theory that the drugs were inhibiting the mitochondria, the researchers flooded isolated mitochondria with large amounts of the drugs and then measured the levels of processed protein in the mitochondria.

They found that a number of HIV-AIDS drugs can inhibit mitochondrial processing.

Although these findings suggest a possible link between HIV-AIDS drugs and mitochondrial dysfunction, Weiner said he believes that investigating the mitochondria of patients in treatment, or using tissue culture grown in the lab, is the next step.

"That is the only way to determine whether actual patients taking the medication are more than just slightly compromised by the effects of the HIV-AIDS medication on their mitochondria."

In the interim, Weiner said drug companies may find this information useful in efforts to make medications with fewer side effects.

"Drug companies making new AIDS protease inhibitors can take the enzyme we used and screen new potential drugs and select ones that can fight the virus but not damage the mitochondria," he said.

Drug manufacturers may not have made the connection to the mitochondria because the drugs’ effects are minor, Weiner said.

"The protease inhibitors were weak inhibitors of the mitochondria’s enzymatic processing system," he said. "If they were better inhibitors, that would have likely led to more serious complications in patients."

Weiner also sees other possible impacts from the research, such as potential anticancer treatments. He said scientists might find a "good way to kill tumors," by inhibiting specific enzymes within the tumors’ own mitochondria.

The research was published in the September issue of the Journal Mitochondrion. Weiner’s portion of the research was funded in part by the National Institutes of Health.

Contact: Beth Forbes, (765) 494-2722; forbes@purdue.edu

Source: Henry Weiner, (765) 494-1650; hweiner@purdue.edu

Ag Communications: (765) 494-2722; Beth Forbes, bforbes@aes.purdue.edu

Purdue News Service: (765) 494-2096; purduenews@purdue.edu

Beth Forbes | EurekAlert!
Further information:
http://www.purdue.edu/
http://www.agriculture.purdue.edu/AgComm/public/agnews/

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>